Medias and publications - Adocia

23 Apr 2020 Adocia announces the release of its Universal Reference Document for the year 2019

20 Apr 2020 Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon

14 Apr 2020 Adocia announces first quarter 2020 financial results and update on the impact of COVID-19

09 Apr 2020 Number of shares and voting rights of ADOCIA as of March 31, 2020

12 Mar 2020 Adocia Announces Full Year 2019 Financial Results

05 Mar 2020 Number of shares and voting rights of ADOCIA as of February 28, 2020

21 Feb 2020 “BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany)

07 Jan 2020 Number of shares and voting rights of ADOCIA as of December 31, 2019

17 Dec 2019 Adocia announces its financial calendar for 2020

11 Dec 2019 Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners

06 Dec 2019 Number of shares and voting rights of ADOCIA as of November 30, 2019

07 Nov 2019 Number of shares and voting rights of ADOCIA as of October 31st, 2019

22 Oct 2019 Adocia Announces Third Quarter 2019 Financial Results

14 Oct 2019 Adocia obtains additional financial resources to accelerate its growth

04 Oct 2019 Number of shares and voting rights of ADOCIA as of September 30, 2019

30 Sep 2019 Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case

10 Sep 2019 Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at EASD

09 Sep 2019 Number of shares and voting rights of ADOCIA as of August 31, 2019

23 Aug 2019 Adocia announces the decision of the American Arbitration Association Tribunal

06 Aug 2019 Number of shares and voting rights of ADOCIA as of July 31st 2019

17 Jul 2019 Adocia Presents First Half 2019 Financial Results

05 Jul 2019 Number of shares and voting rights of ADOCIA as of June 30, 2019

11 Jun 2019 Number of shares and voting rights of ADOCIA as of May 31, 2019

10 Jun 2019 “BioChaperone Glucagon Exenatide (BC Glu Exe), a Stable Combination of Glucagon (Glu) and Exenatide (Exe) Achieved Larger Body Weight (BW) Loss than Exe Alone in DIO Mice” (Poster), Author Dr. Martin Gaudier, June 10, 2019, ADA, San Francisco (USA)

09 Jun 2019 BioChaperone pramlintide insulin (BCPramIns), a new co-formulation of pramlintide (pram) and human insulin (ins), improves post-prandial blood glucose versus both separate injections of pram+ins and insulin lispro (lis) in subjects with T1D”, Dr. Grégory Meiffren, June 9th, 2019, ADA, San Francisco (USA)

06 Jun 2019 Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes

04 Jun 2019 Adocia Announces Scientific Data Presentations at the American Diabetes Association® 79th Scientific Sessions

07 May 2019 Number of shares and voting rights of ADOCIA as of April 30, 2019

15 Apr 2019 Article : Grégory Meiffren PhD, Theresa Herbrand MD, Ernestos Anastassiadis MD, Oliver Klein MD, J. Hans DeVries MD, Tim Heise MD, Bertrand Alluis PhD, Claire Mégret PhD, Martin Gaudier PhD, Olivier Soula PhD, Leona Plum‐Mörschel MD.
“Better glycemic control with BioChaperone® Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM)”
Diabetes Obes Metab., 2019;21(7):15701575.

15 Apr 2019 Adocia announces the release of its Reference Document for the year 2018

15 Apr 2019 Adocia announces first quarter 2019 financial results: cash position and revenue

10 Apr 2019 Adocia announces topline results for the first clinical study of ADO09, a new co-formulation of pramlintide and a prandial insulin

10 Apr 2019 Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris

08 Apr 2019 Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes Obes Metab., 2019;21(7):15701575.

04 Apr 2019 Number of shares and voting rights of ADOCIA as of March 31, 2019

03 Apr 2019 Heise T, Meiffren G, Alluis B, Seroussi C, Ranson A, Arrubla J, Correia J, Gaudier M, Soula O, Soula R, DeVries JH, Klein O, Bode BW.
“BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.”
Diabetes Obes Metab., 2019;21(4):1066-1070.

27 Mar 2019 Comparaison des profils pharmacocinétiques et de pharmacodynamie de l’insuline ultra rapide BioChaperone® Lispro avec les formulations Fiasp® et Novorapid® de l’insuline asparte administrées par pompes à insuline, Dr. Grégory Meiffren, March 27, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)

26 Mar 2019 “BioChaperone Combo, une combinaison fixe d’insuline lispro et d’insuline glargine, améliore les profils de glycémie postprandiale par rapport à un premix d’insuline lispro et les administrations séparées d’insuline lispro et d’insuline glargine dans une étude de phase 1 chez des sujets diabétiques de type 2” (Poster), Author Dr. Claire Mégret, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)

26 Mar 2019 “BioChaperone Glucagon, une formulation de glucagon liquide, stable, prête à l’emploi, est bien tolérée et rétablit rapidement la normoglycemie après une hypoglycémie provoquée par infusion d’insuline” (Poster), Author Mr. Aymeric Ranson, March 26, 2019, Annual Congress of the Francophone of the Diabetes Society, Marseille (France)

13 Mar 2019 Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position

08 Mar 2019 Number of shares and voting rights of ADOCIA as of February 28, 2019

23 Feb 2019 The Ultra-Rapid Insulin BioChaperone® Lispro bolused by insulin pump shows favourable pharmacodynamics and pharmacokinetics vs. faster Aspart and insulin Aspart, Dr. Grégory Meiffren, February 23, 2019, ATTD, Berlin (Germany)

22 Feb 2019 “BioChaperone® Glucagon, A Stable Ready-To-Use Liquid Glucagon Formulation Enabled By Biochaperone Technology, Is Well Tolerated And Quickly Restores Euglycemia After Insulin-Induced Hypoglycemia” (E-Poster Discussion 05), presented by Mr. Aymeric Ranson, February 22, 2019, ATTD, Berlin (Germany)

21 Feb 2019 “BioChaperone® Combo, A Co-Formulation Of Lispro And Glargine, Improves Postprandial Glucose Control Compared To Lispromix25 Or Lispro And Glargine Injections In Type 2 Diabetes Subjects” (EPO2 E-Poster Viewing), presented by Dr. Grégory Meiffren, February 21, 2019, ATTD, Berlin (Germany)

12 Feb 2019 Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019

08 Feb 2019 Number of shares and voting rights of ADOCIA as of January 31, 2019

17 Jan 2019 BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes Obes Metab., 2019;21(4):1066-1070.

News